Maxim Group Maintains Buy on Moleculin Biotech, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Jason McCarthy maintains a Buy rating on Moleculin Biotech (MBRX) but lowers the price target from $45 to $20.
March 26, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Maxim Group maintains a Buy rating on Moleculin Biotech but lowers the price target from $45 to $20.
The reduction in the price target from $45 to $20 by a reputable analyst firm like Maxim Group could lead to a negative short-term sentiment among investors, potentially causing a decrease in MBRX's stock price. The maintenance of a Buy rating indicates underlying confidence in the company's fundamentals, but the significant cut in the price target is likely to have a more immediate impact on investor perception and stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100